Evidence map›Paper›PMID 15352249›Full record

ArticleProteomics2004

Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique.

Paweena Kreunin, Virginia Urquidi, David M Lubman, Steve Goodison

Abstract read
In one paragraph

Article in Proteomics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Integrated gene networks in breast cancer development.Functional & integrative genomics · 2010
    Review
  12. Gradient chromatofocusing-mass spectrometry: a new technique in protein analysis.Journal of the American Society for Mass Spectrometry · 2008
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Genomic signatures of breast cancer metastasis.Cytogenetic and genome research · 2007
    Article
  18. Article
  19. Article
  20. Application of proteomics in the study of tumor metastasis.Genomics, proteomics & bioinformatics · 2004
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Paweena KreuninDepartment of Chemistry, University of Michigan, Ann Arbor, MI, USA.
Virginia Urquidi
David M Lubman
Steve Goodison

Funding

Microsequencing in an Ion Trap/reTOF DeviceR01GM049500 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M. · 1994 to 2016
$3.0M
Functional Analysis of metastasis-Associated ProteinsR01CA108597 · NCI · UNIVERSITY OF FLORIDA · PI GOODISON, STEVE · 2004 to 2008
$1.3M
DIFFERENTIAL PROTEIN EXPRESSION BY MALDI TOF MSR21CA083808 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M. · 2001 to 2002
$214k
NCI NIH HHS R01 CA108597NCI NIH HHS R21CA83808NIGMS NIH HHS R01 GM049500NIGMS NIH HHS R01 GM49500
6 · The paper itself

Abstract

For most cancer cell types, the acquisition of metastatic ability leads to clinically incurable disease. The identification of molecules whose expression is specifically correlated with the metastatic spread of cancer would facilitate the design of therapeutic interventions to inhibit this lethal process. In order to facilitate metastasis gene discovery we have previously characterized a pair of monoclonal cell lines from the human breast carcinoma cell line MDA-MB-435 that have different metastatic phenotypes in immune-compromised mice. In this study, serum-free conditioned media was collected from the cultured monoclonal cell lines and a mass mapping technique was applied in order to profile a component of each cell line proteome. We utilized chromatofocusing in the first dimension to obtain a high resolution separation based on protein pI, and nonporous silica reverse-phase high performance liquid chromatography was used for the second dimension. Selected proteins were identified on the basis of electrospray ionization time of flight mass spectrometry (ESI-TOF MS) intact protein mapping and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) peptide mass fingerprinting. Using this approach we were able to map over 400 proteins and plot them as a 2-D map of pI versus accurate M(r). This was performed over a pI range of 4.0-6.2, and a mass range of 6-80 kDa. ESI-TOF MS data and further analysis using MALDI-TOF MS confirmed and identified 27 differentially expressed proteins. Proteins associated with the metastatic phenotype included osteopontin and extracellular matrix protein 1, whereas the matrix metalloproteinase-1 and annexin 1 proteins were associated with the non-metastatic phenotype. These findings demonstrate that the mass mapping technique is a powerful tool for the detection and identification of proteins in complex biological samples and which are specifically associated with a cellular phenotype.

Indexed as

Neoplasm MetastasisAnimalsBreast NeoplasmsCarcinomaCell Line, TumorCulture Media, ConditionedElectrophoresis, Gel, Two-DimensionalFemaleHumansMiceMolecular Sequence DataNeoplasm ProteinsPhenotypeProteomeSoftwareSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationCulture Media, ConditionedNeoplasm ProteinsProteome

Identifiers

PMID15352249
PMCPMC1702405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.